LLY LLY
Eli Lilly Upgraded to Strong-Buy by Daiwa America
Eli Lilly and Company (NYSE: LLY) received an upgraded rating from Daiwa America on Wednesday, moving the stock from "hold" to "strong-buy." This action...
Eli Lilly Joins Pharma Peers in Urging FDA to Streamline Drug Approvals
Eli Lilly, AbbVie, Johnson & Johnson, and Merck urge the U.S. Food and Drug Administration (FDA) to modify its drug approval process. The firms cite concerns...
🟢 LLY is trading 2.6% up today after bullish Bank of America obesity outlook
LLY is trading at 2.6% up now at $1054.43 after receiving fresh bullish analyst commentary regarding its highly valued obesity franchise. Bank of America...
🟢 LLY is trading 2.6% up today
LLY is trading at +2.6% now at $1054.62, bucking broader market weakness where the S&P 500 is down 0.09% and NASDAQ is down 0.39%. BofA Securities lowered...
🟢 LLY is trading 3.2% up today
LLY is trading at $1060.52 (+3.21%), significantly outperforming a modestly lower market, driven by continuing momentum in its obesity drug portfolio...
🟢 LLY is trading 3.2% up today
LLY is trading at $1060.51 (+3.21%), significantly outperforming the broader market weakness and tech pressures. The gain occurs amid a slightly lower...
Eli Lilly's Retatrutide Phase 3 Results Exceed Expectations, Showing Significant Weight Loss and Pain Relief
Eli Lilly announced highly positive topline results from the Phase 3 TRIUMPH-4 trial for retatrutide, its next-generation obesity drug. The triple agonist...
LLY Shares Trade Modestly Up After Market Close Amid Broader Market Strength
Eli Lilly closed at $991.30 (+0.92%) in after-hours trading on December 10, 2025, showing a modest increase. This slight upward movement aligns with the...
LLY News Summary for December 10, 2025
Recent LLY news includes positive Phase 3 data for Jaypirca (pirtobrutinib) versus Imbruvica for CLL/SLL, showing superior tolerability metrics as of December...
Eli Lilly's Stock Declines for Ninth Consecutive Day Amid Investor Scrutiny
Eli Lilly stock fell for a ninth consecutive day on December 9, 2025, raising investor concerns despite a series of positive strategic announcements. This...
Carolyn Bertozzi Returns to Eli Lilly Board
Eli Lilly announced the election of Nobel Laureate Carolyn R. Bertozzi, Ph.D., as a returning member of its board of directors, effective December 8, 2025. She...
Eli Lilly Invests $6 Billion in New Alabama Manufacturing Facility to Boost Production of Weight-Loss and Diabetes Drugs
Eli Lilly and Company selected Huntsville, Alabama, for a new $6 billion manufacturing plant. Lilly will dedicate the facility to producing Active...
LLY's Dow Exclusion Debated Amid Trillion-Dollar Valuation
Eli Lilly & Co. remains conspicuously absent from the Dow 30, despite briefly topping a $1 trillion market cap on November 21, 2025, driven by blockbuster...
Eli Lilly Gains Key Access to Chinese Market with Inclusion in First Private Insurance Drug Catalog
Eli Lilly's innovative drugs have been included in China's inaugural private insurance catalog, a move set to enhance sales prospects for advanced, high-cost...
Eli Lilly Receives Reaffirmed 'Buy' Rating and Positive Industry Outlook
On December 5, 2025, investment firm Guggenheim reaffirmed its 'buy' rating on Eli Lilly and Company shares, setting a price target of $1,163.00. This reflects...
Eli Lilly Gains Expanded FDA Approval for Cancer Drug Jaypirca
Eli Lilly and Company announced it has received expanded approval from the U.S. Food and Drug Administration (FDA) for its cancer treatment, Jaypirca. The drug...
Eli Lilly and Indiana University Announce $40 Million Research Partnership
Eli Lilly and Company has partnered with Indiana University in a five-year agreement worth up to $40 million to bolster clinical trials and advance research....
Eli Lilly's Pricing Strategy on Obesity Drugs Expected to Pave the Way for Competitors
A new report from PitchBook suggests that recent pricing agreements for GLP-1 obesity treatments by Eli Lilly and Novo Nordisk are setting the stage for new...
LLY Consolidates Near 52-Week Highs Amid Broad Market Weakness; Analyst Targets Remain Bullish
Eli Lilly's stock declined 1.63% on December 1, 2025 to close at $1,057.89, with pre-market trading showing a further 0.15% dip to $1,056.26 on December 2. The...
Eli Lilly to Present at Citi's 2025 Global Healthcare Conference
Eli Lilly and Company is scheduled to participate in the Citi's 2025 Global Healthcare Conference on December 2, 2025. The company will be represented by Ilya...